Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
J Exp Med
; 220(1)2023 01 02.
Article
in English
| MEDLINE | ID: covidwho-2107236
ABSTRACT
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
B-Lymphocytes
/
Interferon Type I
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Qualitative research
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2023
Document Type:
Article
Affiliation country:
Jem.20220258
Similar
MEDLINE
...
LILACS
LIS